Know Cancer

or
forgot password

Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior


Phase 2/Phase 3
18 Years
80 Years
Not Enrolling
Both
Acute Myeloid Leukemia

Thank you

Trial Information

Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior


Inclusion Criteria:



1. Age 18 years to 75 years

2. Able to give informed consent

3. New diagnosis of AML, other than APL or poor-risk AML, as defined in section 3.2,
that has been treated with induction therapy in the last four weeks

4. ECOG performance status of 0 or 1 -

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Relapse free survival

Outcome Time Frame:

2 year

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

J1227

NCT ID:

NCT01588951

Start Date:

July 2012

Completion Date:

June 2017

Related Keywords:

  • Acute Myeloid Leukemia
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimore, Maryland  21231-2410